Lyra Therapeutics is a clinical-stage biotechnology company that is revolutionizing the treatment of chronic rhinosinusitis (CRS). With a focus on providing localized therapies, Lyra is determined to change the status quo for the 14 million people in the United States suffering from this debilitating inflammatory disease. Unlike conventional approaches, Lyra's innovative solutions target the site of treatment, allowing for more effective and long-lasting results.

At the forefront of Lyra's pipeline is LYR-210, a bioresorbable nasal mesh that delivers up to six months of continuous anti-inflammatory medication directly to the sinonasal passages. This groundbreaking product offers hope to CRS patients who often struggle with persistent symptoms and ineffective treatment options. Powered by a high-impact team of experienced drug developers, Lyra combines advanced materials engineering and drug development to create a treatment solution that integrates proven anti-inflammatory medication with cutting-edge technology.

With product candidates on the path to commercialization, Lyra is on the cusp of transforming the lives of CRS patients. Join Lyra Therapeutics at the nexus of materials science and drug development and be a part of the point of possibilities for the future of CRS treatment. Stay up to date with the latest news and advancements as Lyra Therapeutics continues to shape the field of biotechnology